News
Latest news from CHV and our portfolio companies
Featured News
Milestone marks the commercial use of the first and only liquid embolic approved for hypervascular tumor embolization supported by a prospective, randomized, controlled clinical trial BEDFORD, Mass., January 28th, 2026 – Instylla,…
Insights & Impacts: The latest from CHV
January 20, 2026, Boston, MA: Catalyst Health Ventures (CHV), a venture capital firm focused on
Abbott today announced a collaboration with AtaCor Medical to advance a next-generation investigational extravascular implantable
Acquisition adds next-generation CLAAS® AcuFORM™ Technology to Gore’s portfolio CAUTION: Investigational Device. Limited by federal (or United
EyeCool Therapeutics, Inc. is looking forward to participating in BTIG’s 5th Annual Ophthalmology Day on Monday, December 1,
The Velocity System is a next generation percutaneous AVF technology designed to reduce the need
AtaCor Medical, Inc., a privately-held medical device company focused on transforming cardiac rhythm management systems,
PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage company redefining cancer treatment with therapeutics administered
EyeCool Therapeutics, Inc., a clinical-stage medical device company pioneering a novel approach for the treatment
Instylla, Inc. announced premarket approval (PMA) from the FDA for the company’s flagship Embrace hydrogel
EyeCool Therapeutics, Inc., a clinical-stage medical device company pioneering a novel approach for the treatment